8-K: Current report filing
Published on June 1, 2009
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 26, 2009
OPKO Health, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware | 000-26648 | 75-2402409 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
4400 Biscayne Blvd
Suite 1180
Miami, Florida 33137
(Address of Principal Executive Offices)
Suite 1180
Miami, Florida 33137
(Address of Principal Executive Offices)
Registrants telephone number, including area code: (305) 575-4100
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 1.01. Entry into a Material Definitive Agreement.
On May 26, 2009, May 29, 2009, and June 1, 2009, OPKO Health, Inc. (the Company) entered into stock
purchase agreements with seven accredited investors (the Investors) pursuant to which the Company agreed to sell an aggregate of 31 million shares of the Companys Common
Stock (the Shares) in exchange for $31 million. Under the terms of each investment, OPKO issued the Shares at a price of
$1.00 per Share. The Shares are restricted securities and no registration rights have been granted.
The Shares were issued to the Investors in such amounts as set forth below.
Shares | |||||||||||
Purchasers: | Purchased | Amount of Investment | Date of Agreement | ||||||||
Oracle Partners, LP |
4,000,000 | $ | 4,000,000 | May 29, 2009 | |||||||
Oracle Institutional Partners, LP |
1,000,000 | $ | 1,000,000 | May 29, 2009 | |||||||
Vector Group Ltd. |
5,000,000 | $ | 5,000,000 | May 26, 2009 | |||||||
Nora Real Estate S.A. |
1,000,000 | $ | 1,000,000 | May 26, 2009 | |||||||
Chung Chia Company Limited |
9,500,000 | $ | 9,500,000 | June 1, 2009 | |||||||
Grandtime Associates Limited |
6,000,000 | $ | 6,000,000 | June 1, 2009 | |||||||
Gold Sino Assets Limited |
4,500,000 | $ | 4,500,000 | June 1, 2009 |
Phillip Frost, M.D., the Companys Chairman and Chief Executive Officer, may be deemed to
beneficially own 11.5% of Vector Group Ltd.s outstanding stock.
ITEM 3.02. Unregistered Sales of Equity Shares
The information disclosed under Item 1.01 of this report is incorporated into this Item 3.02
in its entirety. The issuance of the Shares is exempt from the registration
requirements under the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof,
because the transaction does not involve a public offering.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OPKO Health, Inc. |
||||
By: | /s/ Steven Rubin | |||
Name: | Steven Rubin | |||
Title: | Executive Vice President, Administration | |||
Date June 1, 2009
3